Overview

A 105-gene lung cancer panel is a next-generation sequencing assay built to surface the driver alterations that steer non-small cell lung cancer therapy. Rather than testing one biomarker at a time, it reads many genes in parallel from a single specimen, giving clinicians a broader map of treatable vulnerabilities from limited tissue.

How It Works

The laboratory extracts nucleic acid from the sample, prepares libraries, and uses hybridization capture to enrich the 105 target genes. A sequencer reads the regions, and bioinformatics calls single-nucleotide variants, insertions, deletions, and copy changes. Because the panel is fixed, reporting is standardized: each alteration maps to a known association with targeted agents.

Indications

The test fits newly diagnosed or metastatic NSCLC where guideline-recommended drivers must be ruled in or out before therapy selection. It is especially useful when tissue is scarce, since one assay replaces several sequential single-gene tests and preserves material for future analysis.

Specimen & Turnaround

Formalin-fixed paraffin-embedded tissue is the usual input, with plasma accepted when tissue is unavailable. Turnaround follows lab capacity and review depth; buyers should confirm the reporting window and whether urgent cases are prioritized.

Storage & Sourcing

Ship specimens under 2–8°C and avoid freeze-thaw cycles that degrade nucleic acid. Source the assay from a laboratory documenting validation, limit of detection, and variant classification standards. GIVE LIFE TIME International links buyers to accredited molecular laboratories with transparent reporting.

For steady volume, negotiate batch pricing and confirm the laboratory can return aligned read data if a clinician wants a second opinion. A clear service agreement should state that turnaround starts at specimen receipt, not at order placement, so expectations stay realistic. Procurement teams serving several clinics should ask for a single reporting template that maps each alteration to locally reimbursed options, which shortens the path from result to prescription. Because tissue is finite, request guidance on minimum input and on whether a plasma reflex is available when the block yields insufficient material. Documenting these contingencies before the first case prevents mid-treatment delays.

FAQ

Q: Why use a 105-gene panel instead of single-gene tests?
One assay covers many drivers from limited tissue and preserves sample for later questions.

Q: What sample types are accepted?
FFPE tissue is standard; plasma is an alternative when tissue is insufficient.

Q: How are results reported to clinicians?
Each alteration is mapped to its known targeted-therapy association in a structured report.